Intervacc AB (SE:IVACC)
:IVACC
Want to see SE:IVACC full AI Analyst Report?
Top Page
Intervacc AB
(IVACC)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr1.00
▲(8.70% Upside)
Action:ReiteratedDate:03/21/26
The score is held back primarily by weak financial performance—persistent losses, deteriorated gross profitability in 2025, and ongoing cash burn—despite a low-debt balance sheet. Technicals are moderately supportive with the price above major moving averages, but momentum indicators are mixed. Valuation remains constrained by negative earnings and no provided dividend yield.
Positive Factors
Low leverage / strong balance sheet
Near-zero debt materially reduces financial risk and interest burden, giving Intervacc durable financial flexibility. Over the next 2–6 months this supports continued R&D and commercialization activities without immediate refinancing pressure, and preserves optionality for partnerships or targeted funding.
Negative Factors
Persistent losses / gross loss in 2025
A gross loss in 2025 despite rising revenue points to structural cost or product-economics issues. Persistent negative margins undermine sustainable profitability, risk further equity erosion, and require corrective measures to restore unit economics before the business can reliably self-fund growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Near-zero debt materially reduces financial risk and interest burden, giving Intervacc durable financial flexibility. Over the next 2–6 months this supports continued R&D and commercialization activities without immediate refinancing pressure, and preserves optionality for partnerships or targeted funding.
Read all positive factors
Intervacc AB (IVACC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr389.21M
Dividend YieldN/A
Average Volume (3M)373.34K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth70.42%
EPS Growth67.58%
CountrySE
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr51.00M
Intervacc AB Business Overview & Revenue Model
Company Description
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for ...
How the Company Makes Money
Intervacc makes money primarily by selling veterinary vaccines, with revenue driven mainly by commercial sales of its equine vaccine Strangvac through distribution and commercialization partners in approved markets. The company’s earnings are ther...
Intervacc AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.09M | 11.79M | 8.02M | 9.68M | 5.24M |
| Gross Profit | -84.86M | -3.53M | -13.81M | 3.37M | 6.25M |
| EBITDA | -66.25M | -58.75M | -68.98M | -57.73M | -23.15M |
| Net Income | -80.81M | -75.52M | -102.85M | -64.16M | -29.38M |
Balance Sheet | |||||
| Total Assets | 294.43M | 187.32M | 259.61M | 265.04M | 329.39M |
| Cash, Cash Equivalents and Short-Term Investments | 160.89M | 34.40M | 88.34M | 45.70M | 115.71M |
| Total Debt | 0.00 | 145.00K | 181.00K | 322.00K | 433.00K |
| Total Liabilities | 19.52M | 24.99M | 21.68M | 14.88M | 21.14M |
| Stockholders Equity | 274.91M | 162.33M | 237.93M | 250.16M | 308.25M |
Cash Flow | |||||
| Free Cash Flow | -66.92M | -53.90M | -47.94M | -75.92M | -48.67M |
| Operating Cash Flow | -65.79M | -53.20M | -45.83M | -69.79M | -25.46M |
| Investing Cash Flow | -1.13M | -706.00K | -2.11M | -6.13M | -23.13M |
| Financing Cash Flow | 193.40M | -36.00K | 90.58M | 5.91M | 50.00K |
Intervacc AB Technical Analysis
Positive
0.92
Price Trends
0.80
Positive
0.85
Positive
0.94
Positive
Market Momentum
0.06
Negative
77.73
Negative
96.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Positive. The current price of 0.92 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.80, and below the 200-day MA of 0.94, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 77.73 is Negative, neither overbought nor oversold. The STOCH value of 96.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IVACC.
Intervacc AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr389.21M | -3.40 | -25.80% | ― | 70.42% | 67.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr226.66M | -44.78 | -16.90% | ― | -23.33% | ― | |
45 Neutral | kr314.13M | -1.89 | -16.51% | ― | ― | 18.65% | |
44 Neutral | kr380.61M | -4.79 | -79.60% | ― | ― | 48.34% | |
43 Neutral | kr119.59M | -1.72 | -199.86% | ― | -39.28% | -16.74% | |
40 Underperform | kr162.11M | -12.73 | -59.78% | ― | ― | 43.31% |
* Healthcare Sector Average
SE:IVACC
Intervacc AB
1.14
0.11
10.66%
SE:XBRANE
Xbrane Biopharma AB
11.00
-13.38
-54.87%
SE:ELIC
Elicera Therapeutics AB
3.34
-0.90
-21.23%
SE:ACE
Ascelia Pharma AB
3.00
-0.26
-7.98%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.41
-5.11
-78.39%
SE:IMMU
Immunicum AB
5.13
0.08
1.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.